Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.64 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.64 |
| ▸ | PI4KA | P42356 | 15/20 | 0.62 |
| ▸ | PI4KB | Q9UBF8 | 15/20 | 0.62 |
| ▸ | PIP5K1C | O60331 | 6/20 | 0.56 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177897 | 0.86 | PIK3CA (0.60) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KA | |
| SCHEMBL1638828 | 0.84 | RAB9A (0.59) | — | |
| SCHEMBL798579 | 0.81 | PIK3CG (0.77) | PIK3CAPIK3CG | |
| SCHEMBL172060 | 0.80 | DHFR (0.47) | DHFR | |
| SCHEMBL4655242 | 0.79 | RAB9A (0.55) | — | |
| SCHEMBL29646253 | 0.79 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KA | |
| SCHEMBL5532470 | 0.79 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KA | |
| SCHEMBL8773471 | 0.78 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KA | |
| SCHEMBL31324976 | 0.77 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KA | |
| SCHEMBL31324975 | 0.77 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CGPIK3CBPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | PIK3CA 15/4885PIK3CD 10/4885PIK3CG 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.